UCLA

UCLA Previously Published Works

Title

Synthesis of highly substituted adamantanones from bicyclo[3.3.1]nonanes.

Permalink

<https://escholarship.org/uc/item/81j206k3>

Journal

The Journal of organic chemistry, 79(21)

ISSN

0022-3263

Authors

Jung, Michael E
Lee, Gloria S

Publication Date

2014-11-01

DOI

10.1021/jo501368d

Peer reviewed

Synthesis of Highly Substituted Adamantanones from Bicyclo[3.3.1]nonanes

Michael E. Jung* and Gloria S. Lee

Department of Chemistry and Biochemistry, University of California, Los Angeles, California 90095-1569, United States

S Supporting Information

ABSTRACT: Trifluoromethanesulfonic acid and other electrophiles promote formation of the adamantanone core from the readily accessible 1,5-dimethyl-3,7-dimethylenebicyclo[3.3.1]nonan-9-one **2**. Because adamantyl cation **3** can be trapped by a range of nucleophiles, including aromatic and heteroaromatic rings, alcohol, nitriles, and halides, access to a wide variety of functionality at the newly formed tertiary position is provided.

The diamond-like structure of adamantane has fascinated chemists since its discovery in petroleum in 1933.¹ Studies have shown that adamantane is the most stable of the C₁₀H₁₆ isomers and can be easily prepared by the Lewis acid promoted rearrangement of other C₁₀H₁₆ species, e.g., tetrahydrodicyclopentadiene.² The first instance of the adamantane structure in drugs involved 1-aminoadamantane, amantadine, a selective antiviral agent, which was used against influenza upon its approval in 1966.³ Since then, a number of 1-aminoadamantanes have been synthesized, and one, 3,5-dimethyl-1-aminoadamantane, memantine, has been approved for the treatment of Alzheimer's disease.⁴ However, the biological mechanism of action of the adamantane derivatives is still unclear.

For a project aimed at the total synthesis of rugulosone, **1**⁵ (Figure 1), we prepared 1,5-dimethyl-3,7-dimethylene-

Figure 1. Rugulosone, amantadine, and memantine structures.

bicyclo[3.3.1]nonan-9-one **2** by the very efficient quadruple alkylation of 3-pentanone with 1,1-bis(chloromethyl)ethylene, a reaction that proceeded in 90% yield.⁶ We were interested to see if this bis(methylene) system could be used to efficiently construct various substituted adamantanones, which might serve as precursors to the corresponding adamantanes. The ability to construct a large variety of substituted adamantanones in a highly efficient and simple manner could allow for more rapid testing of derivatives to study both the biological activity and the mechanism of action of this class of compounds.

The Friedel–Crafts alkylation of benzenoid aromatic rings with the adamantane core has been reported occasionally, but harsh conditions, including high temperature, long reaction times, and high pressure mercury lamps, were often employed.⁷ In many cases, a multistep procedure is involved in which a 1-haloadamantane is first formed and then used to generate a carbocation at the tertiary position, which is subsequently trapped by a nucleophile. Although there is one example of the cyclization of the simple unsubstituted 3,7-dimethylenebicyclo[3.3.1]nonane in anisole as solvent giving the aryl adamantane,⁸ to our knowledge, no systematic study of the Friedel–Crafts alkylation of adamantyl cations generated by this type of cyclization has been carried out. This limited reaction scope therefore prompted us to investigate a more efficient way of rapidly constructing substituted adamantanones.

Synthesis of Adamantanones from 2. We now present a new and efficient method for the construction of adamantan-2-ones substituted at the 7-position with aryl, heteroaryl, alkoxy, amido, and alkynyl groups, starting from the 1,5-dimethyl-3,7-dimethylenebicyclo[3.3.1]nonan-9-one core **2**. We envisioned forming the adamantyl cation with acid, followed by trapping with a nucleophile to obtain the tetrasubstituted adamantanone core. Consequently, we screened various acidic conditions for the formation of the desired product, 1,3,5-trimethyl-7-phenyladamantan-2-one **4a**, from **2** (Table 1).

Without the presence of an added nucleophile, the cation can be quenched by the benzene solvent. Thus, treatment of the diene **2** with trimethylsilyl triflate in benzene afforded the 7-phenyl-substituted adamantanone **4a** in 65% yield. Other protic and Lewis acids produced the same product **4a** in moderate to good yields, with trifluoromethanesulfonic acid, triflic acid, being the best of those tested, giving the desired product in

Received: June 18, 2014

Published: October 2, 2014

Table 1. Conversion of Diene 2 to Trimethylphenyladamantanone 4a^a

entry	acid	yield (%)
1	TMSOTf	65
2	BF ₃ ·OEt ₂	78
3	AlCl ₃	47
4	H ₂ SO ₄	21
5	TFA	59
6	TfOH	90
7	Cu(OTf) ₂	0
8	None	0

^aReaction conditions: 2 (1.05 mmol), acid (1.2 equiv), benzene (5 mL), Ar, 3 h.

90% yield. Some Lewis acid catalysts, e.g., cupric triflate, did not provide any product but only returned starting material.

Substrate Scope. Next, we investigated the substrate scope of our reaction using the same mild conditions and short reaction times (Table 2). Various aromatic rings with electron-

Table 2. Reaction of 2 with Aromatic Rings 5 To Give 4^a

entry	Nu	R ₂	R ₃	R ₄	R ₅	R ₆	yield (%)
1 ^b	5a	H	H	H	H	H	4a, 90
2 ^b	5b	H	H	Me	H	H	4b, 57
		Me	H	H	H	H	4b', 19
3 ^b	5c	Me	H	H	Me	H	4c, 47
4	5d	OMe	H	OMe	H	H	4d, 47
5	5e	OMe	H	OMe	H	OMe	4e, 36

^aReaction conditions: 2 (1.05 mmol), TfOH (1.2 equiv), nucleophile (5.0 equiv), CH₂Cl₂ (5 mL), Ar, 3 h, unless otherwise specified.

^bReactions are performed with nucleophile as solvent.

donating groups 5a–e reacted as good nucleophiles to produce the substituted adamantanones 4a–e in moderate yields. Thus, toluene 5b gave a 76% combined yield of a 3:1 mixture of the 4-methyl and 2-methyl products 4b and 4b'. *p*-Xylene 5c gave the expected product 4c in 47% isolated yield; similarly, *m*-dimethoxybenzene 5d afforded the expected product 4d in 47% yield. The more hindered 1,3,5-trimethoxybenzene 5e gave the expected product 4e in only 36% yield, perhaps due to the steric hindrance of the only available aromatic position. Again, there have been scattered reports of the trapping of adamantyl cations with benzenoid nucleophiles, but no systematic study has been reported.⁹ As far as we can tell, no heterocycles have ever been used to trap an adamantyl cation under these conditions. Therefore, we studied the use of several five-membered heterocyclics in this regard (Table 3). Furan and *N*-methylindole gave very poor results, with a multitude of

Table 3. Reactions of 2 with Nucleophiles To Give 4^a

entry	nuc	R	yield (%)
1			4f, 33
			4f', 17
2			4g, 26
			4g', 21
3 ^b	HOME	OMe	4h, 52
4 ^b	HOAc	OAc	4i, 88
5 ^c	H ₂ O	OH	4j, 74
6	HOCH ₂ CCH	OCH ₂ C≡CH	4k, 35
7	HOPh	OPh	4l, 36
8	HOTf	OSO ₂ CF ₃	4m, trace 4n, trace
9 ^b	CH ₃ CN	NHCOMe	4o, 88
10	TMS-C≡C-H	C≡CH	4p, 44

^aReaction conditions: 2 (1.05 mmol), TfOH (1.2 equiv), nucleophile (5.0 equiv), CH₂Cl₂ (5 mL), unless otherwise specified. ^bReactions performed with nucleophile as solvent. ^cConc. H₂SO₄ as solvent.

unidentified products being formed. However, the reaction of 2 in the presence of triflic acid with *N*-methylpyrrole 5f gave a mixture of the 2- and 3-substituted pyrrole products, 4f and 4f', in yields of 33 and 17%, respectively. The assignment of the structures was based on the pattern of the absorptions in the proton NMR spectrum and matched literature data.¹⁰ In this case, the ratio of the trapping at C2 vs C3 (1.9:1) is somewhat surprising given that the reported ratio of trapping of a *tert*-butyl cation with *N*-methylpyrrole is 1:1.4 (C2/C3).¹¹ Likewise, reaction of 2 with thiophene 5g in the presence of triflic acid afforded the 2- and 3-substituted products, 4g and 4g', in a 1.2:1 ratio in yields of 26 and 21%, respectively. The assignment was made by comparing the coupling constants for the three aromatic protons and by analogy to literature data.¹²

In addition to trapping the adamantyl cation, generated from 2 by protonation with triflic acid, with aromatic nucleophiles, we also investigated trapping with other simple nucleophiles. Again, there are reports of such nucleophilic trapping in the literature,^{8,13} but no systematic study has been carried out. Thus, we treated the diene 2 with triflic acid in the presence of various nucleophiles, with the results shown in Table 3. Methanol and acetic acid as nucleophilic solvents gave good yields of the expected trapping of the oxygen atom to produce 4h and 4i in 52 and 88% yields, respectively. The tertiary alcohol 4j could also be prepared by treating 2 with conc. sulfuric acid in 74% yield. Propargyl alcohol also trapped on oxygen to give the propargyl ether 4k in 35% yield. Somewhat surprisingly, phenol gave trapping only on the oxygen atom to give 4l in 36% yield, with no evidence for trapping on carbon, either C4 or C2, being observed. In the absence of any external

trapping agent, one obtains trace amounts of the triflate **4m** and the symmetrical ether **4n**. One can also carry out a Ritter reaction, namely, treatment of **2** with triflic acid in acetonitrile as solvent to generate the acetamide **4o** in 88% yield.¹⁴ This trapping would be useful for preparing analogues of memantine. Finally, we could also effect C–C bond formation of a nonaromatic substrate, namely, trimethylsilyl acetylene, to give the acetylene product **4p** in 44% yield.

We also examined the addition of electrophiles other than proton to one of the exocyclic methylenes of **2** with the idea of triggering the cyclization to produce the adamantyl cation, which could then be trapped with simple nucleophiles (Table 4). Reports of such dual addition of electrophiles and

Table 4. Reactions of 2 with Both Electrophiles and Nucleophiles To Give 4

entry	conditions	R ₁	R ₂	yield (%)
1	NBS, aq. DMSO	Br	OH	4q , 66
2	NBS, MeOH	Br	OMe	4r , 89
3	Br ₂ , CH ₂ Cl ₂	Br	Br	4s , 88
4	I ₂ , CH ₂ Cl ₂	I	I	4t , 77
5	Hg(OAc) ₂ , MeOH, aq. NaCl	HgCl	OMe	4u , 26

nucleophiles to similar dienes have appeared in the literature,¹⁵ but here again no systematic study has been carried out. Thus, treatment of the diene **2** with *N*-bromosuccinimide (NBS) in aqueous DMSO or in methanol gave the bromomethyl alcohol and methyl ether, **4q** and **4r**, in 66 and 89% yields, respectively. Addition of either bromine or iodine to **2** in dichloromethane gave the dihalo products, **4s** and **4t**, in yields of 88 and 77%, respectively.^{8,16} Nonhalogenated electrophiles could also be used. Thus, addition of mercuric acetate to **2** in methanol provided the acetoxymercurio ether, which, for ease of isolation, was converted into the chloromercurio ether by addition of NaCl to give **4u** in 26% yield.

We tested the generality of this process by examining the cyclization of other substrates, namely, the three analogues of the dimethyl compound **2** with ethyl, propyl, and phenyl groups adjacent to the ketone. The additional di(exo)-methylene compounds, **6a–c**, were prepared from the corresponding substituted ketones and the bis(chloromethyl)-ethylene.⁶ Treatment of all of these three analogues **6a–c** with triflic acid in benzene afforded the expected adamantanone products **7a–c** in good yields (Scheme 1). No attempts at optimization of these yields have been made. Thus, simple alkyl and aryl substituents are well-tolerated.

The mechanism of this process (Scheme 2) would involve the addition of an electrophile, E⁺ (H⁺, X⁺), to one of the two identical alkenes of **2** from the exo face to generate the tertiary carbocation **A**. Cyclization of the other alkene on to this carbocation would then generate the adamantyl cation **B**, despite the instability inherent in a nonplanar cation. Attack of the nucleophile on **B**, with loss of a proton, would afford the observed products **4**. Although the formation of adamantyl cations is well-known,^{7c,17} they are often formed from adamantyl halides and not from bicyclo[3.3.1]diene systems.

Scheme 1. Cyclization of Analogues 6 To Give Adamantanones 7

Scheme 2. Mechanism of 2 Forming Adamantane Core 4

We have shown that the acetamide **4o**, obtained from **2** by the Ritter reaction, can be hydrolyzed to the amine **8**, an analogue of memantine, in 97% yield under strongly acidic conditions (Scheme 3), i.e., conc. HCl in ethanol in a sealed tube at 100 °C for 3 days.

Scheme 3. Hydrolysis of 4o To Give Memantine Analogue 8

In summary, we have shown that the readily available 1,5-dimethyl-3,7-dimethylene-bicyclo[3.3.1]nonan-9-one **2** can be easily converted into a wide variety of adamantanone derivatives by treatment with various electrophiles, especially proton, in the presence of a nucleophilic trapping agent. Other analogues, e.g., **6a–c**, also give the corresponding adamantanones **7a–c**.

EXPERIMENTAL SECTION

General. All reactions were carried out under an argon atmosphere unless otherwise specified. Dichloromethane was distilled from calcium hydride under an argon atmosphere. Trifluoromethanesulfonic acid of 99% purity was used. All other solvents or reagents were purified according to literature procedures. ¹H NMR spectra were recorded on a high-field NMR spectrometer (at 500 MHz) and are reported relative to deuterated solvent signals. Data for ¹H NMR spectra are reported as follows: chemical shift (δ ppm), multiplicity, coupling constant (Hz), and integration. Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and b, broad. ¹³C NMR spectra were recorded on a high-field NMR spectrometer (at 125 MHz). Data for ¹³C NMR spectra are reported in terms of chemical shift and are reported in parts per million (ppm, δ). Thin-layer chromatography (TLC) was carried out using precoated silica gel sheets (Merck 60 F254). Visual detection was performed using phosphomolybdic acid or iodine. Flash chromatography was performed using SilicaFlash P60 (60 Å, 40–63 μm) silica gel with compressed air. High-resolution mass spectrometry

was taken on a quadrupole mass spectrometer equipped with a DART ion source.

General Procedure for Acid-Promoted Cyclization in Benzene. To a solution of diene **2** (0.200 g, 1.05 mmol) in benzene (5 mL) was added trifluoromethanesulfonic acid (0.111 mL, 1.26 mmol) at 0 °C. The reaction was warmed to 21 °C and stirred for 3 h. The solution was quenched with a saturated solution of NaHCO₃ (10 mL). The mixture was extracted with hexanes (3 × 20 mL), and the combined organic extracts were dried with MgSO₄, filtered, and concentrated in vacuo to give a crude yellow oil. Purification by flash column chromatography on silica gel (19:1 hexanes/ethyl acetate) afforded the trimethylphenyladamantanone **4a** (0.253 g, 0.94 mmol, 90%) as a light yellow oil.

General Procedure for the Triflic Acid-Promoted Cyclization and Trapping of Nucleophiles. To a solution of diene **2** (0.200 g, 1.05 mmol) in dichloromethane (5 mL) was added *m*-dimethoxybenzene **5d** (0.030 mL, 5.25 mmol) followed by trifluoromethanesulfonic acid (0.111 mL, 1.26 mmol) at 0 °C. The reaction was warmed to 21 °C and stirred for 3 h. The solution was quenched with a saturated solution of NaHCO₃ (10 mL). The mixture was extracted with dichloromethane (3 × 20 mL), and the combined organic extracts were dried with MgSO₄, filtered, and concentrated in vacuo to give a crude light yellow oil. Purification by flash column chromatography on silica gel (19:1 hexanes/ethyl acetate) afforded the 2,4-dimethoxyphenyladamantanone **4d** (0.162 g, 0.49 mmol, 47%) as a light yellow oil.

General Procedure for the Addition of Various Electrophiles and Subsequent Trapping of Nucleophiles. To a solution of diene **2** (0.100 g, 0.525 mmol) in 1:1 methanol/dichloromethane (6 mL) was added NBS (0.121 g, 0.068 mmol) at 0 °C. The reaction was warmed to 21 °C and stirred for 3 h. The solution was quenched with a saturated solution of NaHCO₃ (10 mL). The mixture was extracted with dichloromethane (3 × 15 mL), and the combined organic extracts were dried with MgSO₄, filtered, and concentrated in vacuo to give crude bromomethyl methoxyadamantanone **4r** (0.140 g, 89%) as a light yellow oil.

1,5-Dimethyl-3,7-dimethylenebicyclo[3.3.1]nonan-2-one, 2. To a suspension of 60% NaH in mineral oil (0.176 g, 4.40 mmol) (washed three times with hexanes) in toluene (5 mL) was added 3-pentanone (0.086 g, 1.00 mmol) in toluene (2 mL) dropwise. A solution of 1-chloro-2-(chloromethyl)-2-propene (0.254 g, 2.20 mmol) in toluene (2 mL) was added dropwise, and the reaction was refluxed overnight. The solution was then cooled to room temperature and quenched with a saturated solution of NH₄Cl (20 mL). The mixture was extracted with ethyl acetate (3 × 20 mL) and washed with brine (20 mL), and the combined organic extracts were dried with MgSO₄, filtered, and concentrated in vacuo to give a crude yellow oil. Purification by flash column chromatography on silica gel (19:1 hexanes/ethyl acetate) afforded the bicyclononanone **2** (0.171 g, 0.90 mmol, 90%) as a light yellow oil.

5-Hydroxy-1,3,7-trimethyladamantan-2-one, 4j. To a solution of the diene **2** (0.050 g, 0.26 mmol) in DMSO (1 mL) were added conc. H₂SO₄ (1 mL) and water (0.1 mL) at 0 °C. The reaction was warmed to room temperature and stirred for 3 h. The solution was quenched with a saturated solution of NaHCO₃ (10 mL) and extracted with dichloromethane (3 × 20 mL), and the combined organic extracts were washed with water (10 mL) and brine (10 mL), dried with MgSO₄, filtered, and concentrated in vacuo to give hydroxyadamantanone **4j** (0.041 g, 0.20 mmol, 74%) as a light yellow oil.

5-Amino-1,3,7-trimethyladamantan-2-one, 8. To a solution of the acetamide **4o** (0.087 g, 0.35 mmol) and ethanol (2 mL) were added conc. HCl (0.5 mL) and water (0.1 mL) in a sealed tube. The vessel was heated at 100 °C for 3 days. The solution was then cooled to 0 °C and quenched with a saturated solution of NaHCO₃ (20 mL). The mixture was extracted with dichloromethane (3 × 20 mL) and washed with brine (20 mL), and the combined organic extracts were dried with MgSO₄, filtered, and concentrated in vacuo to give the crude 5-aminoadamantanone **8** (0.070 g, 0.34 mmol, 97%) as a yellow oil.

1,3,5-Trimethyl-7-phenyladamantan-2-one, 4a. ¹H NMR (500 MHz, CDCl₃) δ 7.38–7.31 (m, 4H), 7.23 (bt, *J* = 7.0 Hz, 1H), 1.98 (bd, *J* = 12 Hz, 2H), 1.88–1.85 (m, 4H), 1.64 (bd, *J* = 12.5 Hz, 2H), 1.57–1.54 (m, 4H), 1.01 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 218.5, 147.7, 128.3, 126.2, 124.9, 52.5, 51.5, 48.1, 45.9, 38.4, 32.1, 28.8, 22.6. HRMS (ESI, *m/z*): 269.1895; calcd for C₁₉H₂₄OH (M + H)⁺, 269.1905.

1,3,5-Trimethyl-7-(4-methylphenyl)adamantan-2-one, 4b, and 1,3,5-Trimethyl-7-(2-methylphenyl)adamantan-2-one, 4b'. ¹H NMR (500 MHz, CDCl₃) δ 7.25 (d, *J* = 8.0 Hz, 2H), 7.16 (d, *J* = 8.0 Hz, 2H), 2.33 (s, 3H), 1.96 (m, 2H), 1.85 (m, 4H), 1.65 (bd, *J* = 12.5 Hz, 2H), 1.54 (m, 2H), 1.00 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 218.6, 144.7, 135.7, 129.1, 124.8, 52.5, 51.5, 48.1, 45.9, 38.5, 32.1, 28.8, 22.8, 20.9. HRMS (ESI, *m/z*): 283.2051; calcd for C₂₀H₂₆OH (M + H)⁺, 283.2062.

5-(2,5-Dimethylphenyl)-1,3,7-trimethyladamantan-2-one, 4c. ¹H NMR (500 MHz, CDCl₃) δ 7.13 (s, 1H), 7.03 (d, *J* = 8.0 Hz, 1H), 6.95 (d, *J* = 7.5 Hz, 1H), 2.55 (s, 3H), 2.32 (s, 3H), 2.07 (m, 4H), 1.99 (s, 2H), 1.64 (d, *J* = 12.0 Hz, 2H), 1.56 (d, *J* = 12.0 Hz, 2H), 1.03 (s, 6H), 1.02 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 218.6, 144.1, 135.4, 133.4, 132.7, 127.0, 126.9, 52.4, 49.8, 46.2, 45.9, 39.9, 32.2, 29.0, 23.2, 22.8, 21.2. HRMS (ESI, *m/z*): 297.2197; calcd for C₂₁H₂₈OH (M + H)⁺, 297.2218.

1,3,5-Trimethyl-7-(2,4-dimethoxyphenyl)adamantan-2-one, 4d. ¹H NMR (500 MHz, CDCl₃) δ 6.46 (s, 1H), 6.44 (m, 2H), 3.80 (s, 3H), 3.79 (s, 3H), 2.15 (d, *J* = 11.5 Hz, 2H), 1.97 (d, *J* = 9 Hz, 2H), 1.55 (m, 6H), 0.98 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 219.4, 159.4, 159.2, 127.5, 126.9, 103.6, 99.7, 55.2, 54.9, 52.7, 49.2, 45.9, 45.8, 38.4, 32.0, 29.0, 22.8. HRMS (ESI, *m/z*): 329.2100; calcd for C₂₁H₂₈O₃H (M + H)⁺, 329.2117.

1,3,5-Trimethyl-7-(2,4,6-trimethoxyphenyl)adamantan-2-one, 4e. ¹H NMR (500 MHz, CDCl₃) δ 6.13 (s, 2H), 3.78 (s, 3H), 3.74 (s, 6H), 2.36 (bd, *J* = 12.5 Hz, 2H), 2.25 (bd, *J* = 12 Hz, 2H), 2.16 (s, 2H), 1.53 (s, 4H), 0.95 (s, 6H), 0.92 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 219.9, 160.5, 158.9, 115.4, 93.1, 55.8, 55.1, 52.5, 50.4, 46.1, 45.8, 41.1, 31.9, 29.3, 23.0. HRMS (ESI, *m/z*): 359.2210; calcd for C₂₂H₃₀O₄H (M + H)⁺, 359.2222.

1,3,5-Trimethyl-7-(1-methyl-1H-pyrrol-2-yl)adamantan-2-one, 4f, and 1,3,5-Trimethyl-7-(1-methyl-1H-pyrrol-3-yl)adamantan-2-one, 4f'. ¹H NMR (500 MHz, CDCl₃) δ 6.53 (t, *J* = 2.5 Hz, 1H), 6.48 (t, *J* = 2.5 Hz, 1.9H), 6.40 (t, *J* = 2.0 Hz, 1H), 6.04 (t, *J* = 2.0 Hz, 1H), 6.01 (t, *J* = 2.5 Hz, 1.9H), 5.94 (t, *J* = 2 Hz, 1.9H), 3.76 (s, 5.7H), 3.60 (s, 3H), 2.05 (d, *J* = 12.0 Hz, 4H), 1.95–1.87 (m, 10H), 1.77 (m, 4H), 1.62 (d, *J* = 12.5 Hz, 4H), 1.60–1.50 (m, 8H), 0.99 (s, 18H), 0.96 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 219.1, 218.2, 138.0, 132.6, 124.4, 121.6, 116.8, 106.1, 105.9, 105.1, 52.7, 52.4, 49.8, 49.1, 46.5, 45.9, 45.6, 37.2, 36.4, 36.1, 34.6, 32.0, 31.8, 28.8, 28.7, 22.65, 22.60. HRMS (ESI, *m/z*): 272.2005; calcd for C₁₈H₂₅NOH (M + H)⁺, 272.2014.

1,3,5-Trimethyl-7-(thiophen-2-yl)adamantan-2-one, 4g, and 1,3,5-Trimethyl-7-(thiophen-3-yl)adamantan-2-one, 4g'. ¹H NMR (500 MHz, CDCl₃) δ 7.28 (dd, *J* = 5.0, 3.0 Hz, 1H), 7.16 (dd, *J* = 5.0, 1.0 Hz, 1H), 7.07 (dd, *J* = 5.0, 1.5 Hz, 1H), 6.98 (dd, *J* = 3.0, 1.5 Hz, 1H), 6.94 (m, 1H), 6.84 (dd, *J* = 3.5, 1.5 Hz, 1H), 2.02 (d, *J* = 12.0 Hz, 2H), 1.97 (d, *J* = 12.0 Hz, 2H), 1.90 (m, 4H), 1.83 (m, 4H), 1.62 (d, *J* = 12 Hz, 4H), 1.56 (m, 4H), 1.00 (s, 18H). ¹³C NMR (125 MHz, CDCl₃) δ 218.3, 217.8, 153.8, 149.8, 126.5, 125.6, 125.3, 122.6, 121.2, 118.2, 52.7, 52.5, 52.4, 51.6, 49.7, 48.4, 46.0, 45.9, 38.1, 37.3, 32.3, 32.0, 28.7, 28.5, 22.5, 22.4. HRMS (ESI, *m/z*): 275.1460; calcd for C₁₇H₂₂OSH (M + H)⁺, 275.1470.

5-Methoxy-1,3,7-trimethyladamantan-2-one, 4h. ¹H NMR (500 MHz, CDCl₃) δ 3.25 (s, 3H), 1.77 (bd, *J* = 15 Hz, 2H), 1.68–1.65 (m, 4H), 1.53 (bd, *J* = 15 Hz, 2H), 1.47–1.43 (m, 2H), 0.98 (s, 3H), 0.97 (s, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 217.3, 72.5, 52.5, 48.8, 47.7, 46.1, 45.4, 33.5, 28.2, 22.2. HRMS (ESI, *m/z*): 223.1689; calcd for C₁₄H₂₂O₂H (M + H)⁺, 223.1698.

3,5,7-Trimethyl-4-oxoadamantan-1-yl Acetate, 4i. ¹H NMR (500 MHz, CDCl₃) δ 2.13–2.02 (m, 6H), 1.97 (s, 3H), 1.52 (s, 4H), 0.96 (bs, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 216.4, 170.1, 79.2, 52.1, 47.7, 46.3, 45.2, 33.8, 28.0, 22.0, 21.9. HRMS (ESI, *m/z*): 251.1638; calcd for C₁₅H₂₂O₃H (M + H)⁺, 251.1647.

5-Hydroxy-1,3,7-trimethyladamantan-2-one, 4j. ^1H NMR (500 MHz, CDCl_3) δ 1.77 (m, 2H), 1.65 (m, 4H), 1.49 (m, 4H), 1.23 (s, 1H), 0.97 (s, 3H), 0.95 (s, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 217.4, 69.0, 52.3, 51.8, 49.8, 46.4, 33.9, 28.1, 22.1. HRMS (ESI, m/z): 209.1538; calcd for $\text{C}_{13}\text{H}_{20}\text{O}_2\text{H}$ ($M + \text{H}$) $^+$, 209.1542.

1,3,5-Trimethyl-7-(prop-2-yn-1-yloxy)adamantan-2-one, 4k. ^1H NMR (500 MHz, CDCl_3) δ 4.14 (d, $J = 2.5$ Hz, 2H), 2.39 (t, $J = 2$ Hz, 1H), 1.83 (bd, $J = 11$ Hz, 2H), 1.73 (s, 2H), 1.75–1.72 (m, 2H), 1.52 (bd, $J = 12.5$ Hz, 2H), 1.46 (bd, $J = 10$ Hz, 2H) 0.98 (s, 3H), 0.97 (s, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 217.0, 81.2, 74.4, 73.6, 52.2, 49.8, 48.1, 46.3, 45.9, 33.7, 28.2, 22.2. HRMS (ESI, m/z): 247.1686; calcd for $\text{C}_{16}\text{H}_{22}\text{O}_2\text{H}$ ($M + \text{H}$) $^+$, 247.1698.

1,3,5-Trimethyl-7-phenoxyadamantan-2-one, 4l. ^1H NMR (500 MHz, CDCl_3) δ 7.28 (bt, $J = 8.5$ Hz, 2H), 7.13 (bt, $J = 7.5$ Hz, 1H), 6.98 (bd, $J = 8.5$ Hz, 2H), 1.91 (bd, $J = 10.5$ Hz, 2H), 1.81 (s, 2H), 1.79–1.78 (m, 2H), 1.52 (bd, $J = 12.5$ Hz, 2H), 1.47–1.44 (m, 2H), 0.98 (s, 3H), 0.97 (s, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 217.0, 153.8, 129.0, 124.7, 124.2, 77.5, 52.3, 49.3, 47.2, 46.4, 33.9, 28.2, 22.2. HRMS (ESI, m/z): 285.1849; calcd for $\text{C}_{19}\text{H}_{24}\text{O}_2\text{H}$ ($M + \text{H}$) $^+$, 285.1855.

3,5,7-Trimethyl-4-oxoadamantan-1-yl Trifluoromethanesulfonate, 4m. ^1H NMR (500 MHz, CDCl_3) δ 1.79 (m, 2H), 1.70 (bs, 2H), 1.77 (bd, $J = 13.0$ Hz, 2H), 1.52 (bd, $J = 15.0$ Hz, 2H), 1.47 (m, 2H), 0.99 (s, 3H), 0.96 (s, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 217.1, 69.3, 52.2, 51.5, 49.6, 46.3, 33.9, 27.9, 21.8. GC-MS (EI $^+$): found, 340.1; calcd for $\text{C}_{14}\text{H}_{19}\text{F}_3\text{O}_4\text{S}$, 340.0.

7,7'-Oxybis(1,3,5-trimethyladamantan-2-one), 4n. ^1H NMR (500 MHz, CDCl_3) δ 1.89 (d, $J = 11.5$ Hz, 4H), 1.78 (m, 4H), 1.56 (s, 4H), 1.48 (m, 8H), 0.97 (s, 6H), 0.96 (s, 12H). ^{13}C NMR (125 MHz, CDCl_3) δ 217.5, 75.2, 52.3, 52.2, 50.1, 46.6, 33.9, 28.5, 22.4. GC-MS (EI $^+$): found, 398.4; calcd for $\text{C}_{26}\text{H}_{38}\text{O}_3$, 398.3.

N-(3,5,7-Trimethyl-4-oxoadamantan-1-yl)acetamide, 4o. ^1H NMR (500 MHz, CDCl_3) δ 5.41 (bs, 1H), 1.97 (s, 4H), 1.94 (s, 2H), 1.90 (s, 3H), 1.51 (s, 4H), 0.94 (s, 9H). ^{13}C NMR (125 MHz, CDCl_3) δ 217.2, 169.8, 52.9, 52.3, 48.5, 45.9, 45.8, 32.7, 28.2, 24.5, 22.2. HRMS (ESI, m/z): 250.1799; calcd for $\text{C}_{15}\text{H}_{23}\text{NO}_2\text{H}$ ($M + \text{H}$) $^+$, 250.1807.

5-Ethynyl-1,3,7-trimethyladamantan-2-one, 4p. ^1H NMR (500 MHz, CDCl_3) δ 2.13 (s, 1H), 1.91 (bd, $J = 12.5$ Hz, 2H), 1.83–1.80 (m, 4H), 1.52–1.47 (m, 4H), 0.95 (s, 6H), 0.94 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 217.1, 89.4, 68.0, 52.2, 50.5, 47.5, 45.5, 31.5, 31.3, 28.5, 22.3. HRMS (ESI, m/z): 217.1581; calcd for $\text{C}_{15}\text{H}_{21}\text{OH}$ ($M + \text{H}$) $^+$, 217.1592.

5-(Bromomethyl)-7-hydroxy-1,3-dimethyladamantan-2-one, 4q. ^1H NMR (500 MHz, CDCl_3) δ 3.27 (s, 2H), 2.60 (s, 1H), 1.79 (m, 4H), 1.69 (m, 2H), 1.59 (s, 4H), 0.99 (s, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 216.1, 68.8, 51.7, 48.3, 46.1, 45.9, 43.5, 37.7, 22.0. HRMS (ESI, m/z): 287.0628; calcd for $\text{C}_{13}\text{H}_{19}\text{BrO}_2\text{H}$ ($M + \text{H}$) $^+$, 287.0647.

5-(Bromomethyl)-7-methoxy-1,3-dimethyladamantan-2-one, 4r. ^1H NMR (500 MHz, CDCl_3) δ 3.27 (s, 2H), 3.25 (s, 3H), 1.78–1.70 (m, 6H), 1.62–1.56 (m, 4H), 1.00 (s, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 216.2, 72.5, 49.1, 48.5, 47.7, 45.7, 43.7, 41.9, 37.3, 22.2. HRMS (ESI, m/z): 301.0785; calcd for $\text{C}_{14}\text{H}_{21}\text{BrO}_2\text{H}$ ($M + \text{H}$) $^+$, 301.0803.

5-Bromo-7-(bromomethyl)-1,3-dimethyladamantan-2-one, 4s. ^1H NMR (500 MHz, CDCl_3) δ 3.23 (s, 2H), 2.33 (m, 2H), 2.21 (m, 2H), 1.67 (s, 4H), 0.99 (s, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 214.2, 59.1, 55.5, 49.5, 48.0, 47.6, 42.9, 38.7, 21.8. HRMS (ESI, m/z): 348.9797; calcd for $\text{C}_{13}\text{H}_{18}\text{Br}_2\text{OH}$ ($M + \text{H}$) $^+$, 348.9803.

5-Iodo-7-(iodomethyl)-1,3-dimethyladamantan-2-one, 4t. ^1H NMR (500 MHz, CDCl_3) δ 3.06 (s, 2H), 2.52 (s, 2H), 2.51 (d, $J = 11.0$ Hz, 2H), 2.41 (d, $J = 12.5$ Hz, 2H), 1.75 (d, $J = 12.0$ Hz, 2H), 1.68 (d, $J = 11.5$ Hz, 2H), 0.98 (s, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 214.2, 58.8, 53.7, 49.0, 48.6, 39.9, 37.5, 21.6, 19.1. HRMS (ESI, m/z): 444.9519; calcd for $\text{C}_{13}\text{H}_{18}\text{I}_2\text{OH}$ ($M + \text{H}$) $^+$, 444.9525.

7-Methoxy-3,5-dimethyl-4-oxoadamantan-1-yl)methylmercury(II) chloride, 4u. ^1H NMR (400 MHz, CDCl_3) δ 3.16 (s, 3H), 2.05 (s, 2H), 1.67 (m, 4H), 1.55 (m, 4H), 1.44 (m, 4H), 0.89 (s, 6H).

1,3-Diethyl-5-methyl-7-phenyladamantan-2-one, 7a. ^1H NMR (500 MHz, CDCl_3) δ 7.39 (bd, $J = 8.4$ Hz, 2H), 7.34 (bt, $J = 7.6$ Hz, 2H), 7.22 (bt, $J = 6.8$ Hz, 1H), 1.94 (bd, $J = 12$ Hz, 2H), 1.87 (s, 2H), 1.84 (bd, $J = 12.4$ Hz, 2H), 1.56 (m, 4H), 1.47 (qd, $J = 7.2$, 2.4 Hz, 4H), 1.04 (s, 3H), 0.85 (t, $J = 7.6$ Hz, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 218.0, 147.9, 128.2, 126.1, 124.8, 49.3, 48.6, 48.55, 48.50, 37.9, 31.6, 29.1, 28.3, 7.8. HRMS (ESI, m/z): 297.2209; calcd for $\text{C}_{21}\text{H}_{28}\text{OH}$ ($M + \text{H}$) $^+$, 297.2218.

5-Methyl-7-phenyl-1,3-dipropyladamantan-2-one, 7b. ^1H NMR (500 MHz, CDCl_3) δ 7.38 (bd, $J = 8.0$ Hz, 2H), 7.34 (bt, $J = 7.5$ Hz, 2H), 7.23 (bt, $J = 7.0$ Hz, 1H), 1.95 (bd, $J = 12.5$ Hz, 2H), 1.86 (s, 2H), 1.85 (d, $J = 12$ Hz, 2H), 1.60 (d, $J = 12.5$ Hz, 2H), 1.55 (d, $J = 12.5$ Hz, 2H), 1.38 (m, 4H), 1.28 (m, 4H), 1.02 (s, 3H), 0.92 (t, $J = 7.0$ Hz, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 218.1, 148.0, 128.4, 126.2, 124.9, 50.0, 49.1, 48.8, 48.6, 38.4, 38.0, 31.8, 29.3, 16.7, 15.0. HRMS (ESI, m/z): 325.2522; calcd for $\text{C}_{23}\text{H}_{32}\text{OH}$ ($M + \text{H}$) $^+$, 325.2531.

5-Methyl-1,3,7-triphenyladamantan-2-one, 7c. ^1H NMR (500 MHz, CDCl_3) δ 7.51 (d, $J = 7.0$ Hz, 2H), 7.42–7.20 (m, 13H), 2.81 (d, $J = 12.0$ Hz, 2H), 2.45 (d, $J = 12.5$ Hz, 2H), 2.38 (d, $J = 12.5$ Hz, 2H), 2.09 (d, $J = 12.5$ Hz, 2H), 2.05 (s, 2H), 1.28 (s, 6H), 1.24 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 212.7, 147.4, 142.8, 128.9, 128.8, 128.6, 128.1, 127.1, 126.6, 54.0, 50.7, 49.8, 48.2, 38.6, 32.4, 29.7. HRMS (ESI, m/z): 393.2204; calcd for $\text{C}_{29}\text{H}_{28}\text{OH}$ ($M + \text{H}$) $^+$, 393.2218.

5-Amino-1,3,7-trimethyladamantan-2-one, 8. ^1H NMR (500 MHz, CDCl_3) δ 1.65 (d, $J = 11.5$ Hz, 2H), 1.53 (m, 4H), 1.43 (d, $J = 11.5$ Hz, 2H), 1.24 (s, 2H), 0.96 (s, 3H), 0.94 (s, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 218.0, 53.3, 52.4, 50.8, 46.0, 33.1, 28.2, 22.2. HRMS (ESI, m/z): 208.1691; calcd for $\text{C}_{13}\text{H}_{21}\text{NOH}$ ($M + \text{H}$) $^+$, 208.1701.

■ ASSOCIATED CONTENT

Supporting Information

NMR spectra for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: jung@chem.ucla.edu.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This material is based on work supported by the National Science Foundation under equipment grant no. CHE-1048804.

■ REFERENCES

- (1) Landa, S.; Machacek, V. *Collect. Czech. Chem. Commun.* **1933**, *5*, 1.
- (2) (a) Schleyer, P. v. R. *J. Am. Chem. Soc.* **1957**, *79*, 3292. (b) Schleyer, P. v. R.; Donaldson, M. M.; Nicholas, R. D.; Cupas, C. *Org. Synth.* **1973**, *5*, 16.
- (3) For selected publications on adamantanes in medicinal chemistry, see: (a) Wanka, L.; Iqbal, K.; Schreiner, P. R. *Chem. Rev.* **2013**, *113*, 3516. (b) Lamoureux, G.; Artavia, G. *Curr. Med. Chem.* **2010**, *17*, 2967. (c) Schwab, R. S.; England, A. C., Jr.; Poskanzer, D. C.; Young, R. R. *J. Am. Med. Assoc.* **1969**, *208*, 1168. (d) Rapala, R. T.; Kraay, R. J.; Gerzon, K. *J. Med. Chem.* **1965**, *8*, 580. (e) Gerzon, K.; Kau, D. *J. Med. Chem.* **1967**, *10*, 189.
- (4) (a) Gerzon, K.; Krumalns, E. V.; Brindle, R. L.; Marshall, F. J.; Root, M. A. *J. Med. Chem.* **1963**, *6*, 760. (b) Scherm, M.; Peter, D.; Jamiak, B. Ger. Offen. Patent DE2219256, Nov. 8, 1973.
- (5) Moosophon, P.; Kanokmedhakul, S.; Kanokmedhakul, K.; Soyong, K. *J. Nat. Prod.* **2009**, *72*, 1442.
- (6) Jung, M. E.; Lee, G. S.; Pham, H. V.; Houk, K. N. *Org. Lett.* **2014**, *16*, 2382.

- (7) (a) Aigami, K.; Inamoto, Y.; Takaishi, N.; Hattori, K.; Takatsuki, A.; Tamura, G. *J. Med. Chem.* **1975**, *18*, 713. (b) Olah, G. A.; Farooq, O.; Farnia, M. F.; Wu, A. *J. Org. Chem.* **1990**, *55*, 1516. (c) Olah, G. A.; Prakash, G. K. S.; Shih, J. G.; Krishnamurthy, V. V.; Mateescu, G. D.; Liang, G.; Sipos, G.; Buss, V.; Gund, T. M.; Scheleyer, P. v. R. *J. Am. Chem. Soc.* **1985**, *107*, 2764. (d) Olah, G. A.; Lee, C. S.; Prakash, G. K. S.; Moriarty, R. M.; Rao, M. S. C. *J. Am. Chem. Soc.* **1993**, *115*, 10728. (e) Olah, G. A.; Török, B.; Shamma, T.; Török, M.; Prakash, G. K. S. *Catal. Lett.* **1996**, *42*, 5. (f) Prakash, G. K. S.; Yan, P.; Török, B.; Bucsi, I.; Tanaka, M.; Olah, G. A. *Catal. Lett.* **2003**, *85*, 1. (g) Olah, G. A.; Krishnamurti, R.; Prakash, G. K. S. *Synthesis* **1990**, 646.
- (8) Stetter, H.; Gärtner, J. *Chem. Ber.* **1966**, *99*, 925.
- (9) (a) Kozlikovskii, Ya. B.; Koschii, V. A.; Rodionov, V. N.; Yurchenko, A. G.; Mudryi, A. P. *Russ. J. Org. Chem.* **1988**, *24*, 2337. (b) Kozlikovskii, Ya. B.; Koschii, V. A.; Rodionov, V. N.; Yurchenko, A. G.; Mudryi, A. P. *Russ. J. Org. Chem.* **1989**, *25*, 294. (c) Gubernatorov, V. K.; Kogai, B. E.; Sokolenko, V. A. *Izv. Akad. Nauk, Ser. Khim.* **1983**, 1203.
- (10) The 2-substituted isomer has one absorption at low field, δ 6.48, and two absorptions at higher field, δ 6.01 and 5.94, whereas the pattern for the 3-substituted isomer was the opposite, namely, two absorptions at low field, δ 6.53 and 6.40, and one absorption at higher field, δ 6.04. For similar examples, see: von der Saal, W.; Reinhardt, R.; Stawitz, J.; Quast, H. *Eur. J. Org. Chem.* **1998**, 1645.
- (11) Iovel, I.; Fleisher, M.; Popelis, Yu.; Shimanska, M.; Lukevits, E. *Chem. Heterocycl. Compd.* **1995**, *31*, 140.
- (12) (a) Sánchez-Mendoza, E.; Hernández-Trujillo, J. *Magn. Reson. Chem.* **2010**, *48*, 866. (b) Lukevics, E. Ya.; Ignatovich, L. M.; Goldberg, Yu. S.; Shymanskaya, M. U. *Khim. Geterotsikl. Soedin.* **1986**, 853.
- (13) (a) Sohar, P.; Kuzmann, J.; Neder, A. *Tetrahedron* **1986**, *42*, 2523. (b) Stetter, H.; Lennartz, J. *Liebigs Ann. Chem.* **1977**, 1807.
- (14) Olah, G. A.; Gupta, B. G. B. *J. Org. Chem.* **1980**, *45*, 3532.
- (15) (a) Serguchev, Y. A.; Ponomarenko, M. V.; Lourie, L. F.; Chernega, A. N. *J. Fluorine Chem.* **2003**, *123*, 207. (b) Kogai, B. E.; Gubernatorov, V. K.; Sokolenko, V. A. *Zh. Org. Khim.* **1984**, *20*, 2554.
- (16) (a) Chizhov, O. S.; Novikov, S. S.; Karpenko, N. F.; Yurchenko, A. G. *Izv. Akad. Nauk, Ser. Khim.* **1972**, 1510. (b) Stepanov, F. N.; Baklan, V. F.; Isaev, S. D. *Zh. Org. Khim.* **1965**, *1*, 280.
- (17) Schleyer, P. v. R.; Fort, R. C.; Watts, W. E.; Comisarow, M. B.; Olah, G. A. *J. Am. Chem. Soc.* **1964**, *86*, 4195.